Tests a glucose sensor device in kidney transplant patients with diabetes
Tests a continuous glucose monitor in adults with diabetes after kidney transplant.
Key facts
- Who runs it
- University of California, Davis
- Where
- Sacramento, United StatesSee the site
- Trial code
- Registry title
- Use of CGM in Kidney Transplant Recipients
- Status
- Recruiting
- People taking part
- 80 people, planned
- Started
- 29 Jun 2021
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexcom G6
- Dexcom G6 blinded sensor
- Record updated
- 29 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes on insulin who had a kidney transplant within the past year and whose new kidney works.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Kidney transplant within the past year, with a working kidney (eGFR > 30 mL/min); type 2 diabetes treated with insulin.
- Earlier treatment
- Must be taking insulin. People taking hydroxyurea cannot join.
Main reasons for not taking part
- Type 1 diabetes
- Taking hydroxyurea
- Pregnant, planning pregnancy during the study, or breastfeeding
- Unstable heart or blood vessel disease
- Currently in treatment for active cancer
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Received a kidney transplant within the past year with functioning kidney (eGFR > 30 mL/min
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age 18 or above
- Received a kidney transplant within the past year with functioning kidney (eGFR > 30 mL/min
- Person with Type 2 Diabetes and on insulin
- Access to home wi-fi connection
Who cannot take part
- Person with Type 1 Diabetes
- Presence of clinically significant visual or cognitive impairment
- Presence of clinically unstable cardiovascular disease
- Active malignancy treatment
- Must be able to test blood glucose with meter 4x a day when on blinded CGM
- Patients taking hydroxyurea
- Patient unable to wear the Dexcom G6 device at all times for any reason
- Illiterate
- Prisoners
- Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding
Where in United States
- UC Davis HealthSacramento, United StatesContact: Dahlia Zuidema, PharmDTaking people
About the trial
What the trial wants to find out
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
The 2 groups in the trial
- Continuous glucose monitoring (CGM)Existing treatment, for comparison
Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
Treatment: Dexcom G6
- Self monitoring of blood glucose (fingersticks)Placebo, for comparison
The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
Treatment: Dexcom G6 blinded sensor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients
- Plain-language title
- Tests a glucose sensor device in kidney transplant patients with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 January 2026